![Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer](https://www.mdpi.com/cancers/cancers-13-04655/article_deploy/html/images/cancers-13-04655-g001.png)
Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
![Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00352-3/MediaObjects/41523_2021_352_Fig1_HTML.png)
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer
![Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer](https://www.mdpi.com/cancers/cancers-13-04655/article_deploy/html/images/cancers-13-04655-g002-550.jpg)
Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
![Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-021-00352-3/MediaObjects/41523_2021_352_Fig4_HTML.png)
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer
![Cancers | Free Full-Text | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy Cancers | Free Full-Text | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy](https://www.mdpi.com/cancers/cancers-11-00628/article_deploy/html/images/cancers-11-00628-g001-550.jpg)
Cancers | Free Full-Text | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
![Ioannis ZERDES | Postdoctoral Researcher / Resident in Medical Oncology | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology | Research profile Ioannis ZERDES | Postdoctoral Researcher / Resident in Medical Oncology | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology | Research profile](https://www.researchgate.net/profile/Alexios-Matikas/publication/365927137/figure/fig2/AS:11431281104184106@1669965340828/figure-fig2_Q320.jpg)